Biofrontera Inc. BFRIW
Set alert
As of Oct 30, 3:57 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0971
- Prev close
- 0.0014
- Mkt cap
- 796.65K
- Vol
- 37.97K
- Avg vol
- 0
- EPS
- -1.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0014
- High
- 0.0014
- Forward P/E
- 0.00
- Beta
- 0.51
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
News
3 weeks ago globenewswire.com
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol
1 month ago globenewswire.com
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for…
2 months ago globenewswire.com
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of…
5 months ago globenewswire.com
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of…